Education
About Us
Working with TipRanks
Follow Us
Basilea Pharmaceutica (CH:BSLN)
:BSLN
Earnings Data
Report Date
Aug 19, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
1.39Last Year’s EPS
1.58Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 18, 2025
|% Change Since: 17.87%
|Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a strong financial performance with substantial growth in key products like Cresemba and new approvals for Zevtera. The company secured significant non-dilutive funding and expanded its pipeline, although it faced challenges with the tonabacase development. Overall, the positive aspects significantly outweigh the few lowlights.Company Guidance
During the Basilea Pharmaceutica Full-Year Results 2024 Conference Call, the company provided guidance on several key metrics. Cresemba, their leading antifungal product, saw a 20% increase in global in-market sales, surpassing $0.5 billion for the year ending September 2024. This growth contributed to a 30% year-on-year increase in Cresemba and Zevtera-related revenue. Basilea reported a tripling of operating profit and a five-fold increase in operating cash flow compared to 2023, ending the year with a strong cash position and net cash. Total revenue for 2024 grew by 32% to CHF208.5 million, with Cresemba and Zevtera-related revenue reaching CHF194.9 million. The company achieved a net profit of CHF77.6 million, supported by a CHF17.3 million deferred tax asset gain. For 2025, Basilea expects total revenue to grow to approximately CHF220 million, supported by a 14% increase in royalty income and reimbursements from BARDA and CARB-X. Operating profit is anticipated to remain high at around CHF62 million, despite an expected 14% increase in R&D expenses. The company plans to maintain its focus on expanding its pipeline in antifungals and antibacterials while leveraging non-dilutive funding to support its research and development efforts.Strong Financial Performance
Basilea reported a tripling of operating profit and a five-fold increase in operating cash flow for 2024. Total revenue grew by 32% to CHF208.5 million, with Cresemba and Zevtera-related revenue increasing by 30% year-on-year.
Cresemba Sales Growth
Cresemba achieved a 20% increase in global in-market sales, totaling over $0.5 billion for the 12-month period ending September 2024. It remains the largest branded antifungal for invasive fungal infections worldwide.
Zevtera U.S. Approval
Zevtera received FDA approval for a broad range of indications in the U.S., with Innoviva Specialty Therapeutics as the commercialization partner.
Non-Dilutive R&D Funding
Basilea secured significant non-dilutive funding, including up to $268 million from BARDA and additional grants from CARB-X to support antifungal and antibiotic development.
Pipeline Expansion
Significant progress was made in expanding the pipeline, including the initiation of Phase 3 studies for fosmanogepix, development of BAL2420, and acquisition of LptA inhibitors.
---
CH:BSLN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CH:BSLN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 18, 2025 | CHF40.85 | CHF44.25 | +8.32% |
| Aug 13, 2024 | CHF37.85 | CHF41.00 | +8.32% |
| Feb 13, 2024 | CHF33.55 | CHF36.50 | +8.79% |
| Aug 15, 2023 | CHF42.40 | CHF47.35 | +11.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Basilea Pharmaceutica (CH:BSLN) report earnings?
Basilea Pharmaceutica (CH:BSLN) is schdueled to report earning on Aug 19, 2025, TBA Not Confirmed.
What is Basilea Pharmaceutica (CH:BSLN) earnings time?
Basilea Pharmaceutica (CH:BSLN) earnings time is at Aug 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Basilea Pharmaceutica stock?
The P/E ratio of Basilea Pharmaceutica is N/A.
What is CH:BSLN EPS forecast?
CH:BSLN EPS forecast for the fiscal quarter 2025 (Q2) is 1.39.
---